PRISM BioLab Co

PRISM BioLab Co Payables Turnover

The Payables Turnover Ratio of PRISM BioLab Co (206A.T) as of Oct 22, 2026 is 5.18. In the previous year, Payables Turnover Ratio was 2.52 — a change of 105.83% (higher).

Payables Turnover

5.18

YoY

105.83%

Last updated:

Payables Turnover Ratio of PRISM BioLab Co is 2025 5.18 . Payables Turnover Ratio of PRISM BioLab Co was 2024 2.52 . It decreases by 105.83% higher compared to the previous year.

The PRISM BioLab Co Payables Turnover history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Payables Turnover
Date
Payables Turnover
Jan 1, 2022
0.69 JPY
Jan 1, 2023
0.85 JPY
Jan 1, 2024
2.52 JPY
Jan 1, 2025
5.18 JPY
The PRISM BioLab Co Payables Turnover history
YEARPayables TurnoverYoY
5.18+105.83%
2.52+197.67%
0.85+23.18%
0.69—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PRISM BioLab Co Stock analysis

What does PRISM BioLab Co do? PRISM BioLab Co Ltd generates revenue through two distinct business models in the pharmaceuticals sector. The in-house development business focuses on selecting drug discovery targets and creating programs internally using their PepMetics technology platform. The joint development business collaborates with pharmaceutical companies to develop drug discovery programs leveraging their proprietary PepMetics technology. Both models utilize the company's owned drug discovery platform to create new pharmaceutical products. The company's primary clients are pharmaceutical companies seeking to develop new drugs through partnerships with PRISM BioLab's technology. PRISM BioLab's business model centers on its PepMetics technology, which serves as the foundation for both its in-house development and joint development segments. The company builds new drug discovery platforms and develops new drugs through these segments, targeting pharmaceutical companies as their main customers. The firm's research and development activities are conducted using their owned technology, which differentiates their approach in the drug discovery market. The company's revenue streams are derived from pharmaceutical companies that partner with PRISM BioLab for drug discovery programs. By utilizing their PepMetics technology platform, the company creates targeted drug discovery solutions that are developed either internally or in collaboration with pharmaceutical partners. This approach allows PRISM BioLab to generate income through both direct development efforts and collaborative projects with industry clients. PRISM BioLab Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PRISM BioLab Co stock

Payables Turnover Ratio of PRISM BioLab Co is 5.18 in 2025.

Payables Turnover Ratio of PRISM BioLab Co changed from 2.52 to 5.18, representing a 105.83% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Payables Turnover Ratio PRISM BioLab Co since 2006 – with annual values, charts, and detailed analysis.

Payables turnover measures how quickly a company pays its suppliers. Lower turnover may indicate better payment terms or cash flow management.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Payables Turnover Ratio's PRISM BioLab Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Payables Turnover Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Payables Turnover Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — PRISM BioLab Co

All Key Metrics — PRISM BioLab Co